OTCMKTS:MRMD MariMed (MRMD) Stock Price, News & Analysis $0.09 +0.00 (+0.70%) As of 07/3/2025 12:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About MariMed Stock (OTCMKTS:MRMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MariMed alerts:Sign Up Key Stats Today's Range$0.08▼$0.0950-Day Range$0.07▼$0.1152-Week Range$0.07▼$0.29Volume107,597 shsAverage Volume331,697 shsMarket Capitalization$33.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company Overview MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts. Read More MariMed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks5th Percentile Overall ScoreMRMD MarketRank™: MariMed scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for MariMed.Read more about MariMed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of MariMed is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MariMed is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMariMed has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about MariMed's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.02% of the float of MariMed has been sold short.Short Interest Ratio / Days to CoverMariMed has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MariMed has recently increased by 28.73%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMariMed does not currently pay a dividend.Dividend GrowthMariMed does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.02% of the float of MariMed has been sold short.Short Interest Ratio / Days to CoverMariMed has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MariMed has recently increased by 28.73%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for MariMed this week, compared to 1 article on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MariMed insiders have not sold or bought any company stock.Percentage Held by Insiders18.99% of the stock of MariMed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.18% of the stock of MariMed is held by institutions.Read more about MariMed's insider trading history. Receive MRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MariMed and its competitors with MarketBeat's FREE daily newsletter. Email Address MRMD Stock News HeadlinesMariMed Statement Regarding the Commencement of Adult-Use Cannabis Sales in Delaware on August 1stJuly 1, 2025 | globenewswire.comMariMed Inc. (MRMD) Latest Stock News & Headlines - Yahoo FinanceJune 24, 2025 | finance.yahoo.comI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.July 5 at 2:00 AM | Porter & Company (Ad)MariMed’s Premium Nature’s Heritage Brand Enters Functional Mushroom Market Launching Plant-Based MycroDoseMay 29, 2025 | uk.finance.yahoo.comMariMed's Premium Nature's Heritage Brand Enters Functional Mushroom Market Launching Plant-Based MycroDoseMay 29, 2025 | globenewswire.comEarnings call transcript: Marimed’s Q1 2025 revenue flat, stock edges upMay 9, 2025 | investing.comMariMed Inc. (PNK:MRMD) Q1 2025 Earnings Call TranscriptMay 9, 2025 | insidermonkey.comMariMed Inc (MRMD) Q1 2025 Earnings Call Highlights: Strategic Expansion Amidst Market ChallengesMay 9, 2025 | finance.yahoo.comSee More Headlines MRMD Stock Analysis - Frequently Asked Questions How have MRMD shares performed this year? MariMed's stock was trading at $0.1158 at the beginning of the year. Since then, MRMD stock has decreased by 25.7% and is now trading at $0.0860. How were MariMed's earnings last quarter? MariMed Inc. (OTCMKTS:MRMD) announced its earnings results on Wednesday, May, 7th. The company reported ($0.01) EPS for the quarter, meeting analysts' consensus estimates of ($0.01). The business had revenue of $37.96 million for the quarter, compared to analysts' expectations of $38.33 million. MariMed had a negative trailing twelve-month return on equity of 10.21% and a negative net margin of 10.33%. Read the conference call transcript. How do I buy shares of MariMed? Shares of MRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MariMed own? Based on aggregate information from My MarketBeat watchlists, some other companies that MariMed investors own include Canopy Growth (CGC), Innovative Industrial Properties (IIPR), NVIDIA (NVDA), Curaleaf (CURLF), Aurora Cannabis (ACB), Meta Platforms (META) and Tilray Brands (TLRY). Company Calendar Last Earnings5/07/2025Today7/05/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:MRMD Previous SymbolOTC:MRMD CIK1522767 Webmarimedadvisors.com Phone(617) 795-5140FaxN/AEmployees260Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.16 million Net Margins-10.33% Pretax Margin-4.40% Return on Equity-10.21% Return on Assets-3.12% Debt Debt-to-Equity Ratio1.21 Current Ratio1.05 Quick Ratio0.37 Sales & Book Value Annual Sales$157.96 million Price / Sales0.21 Cash Flow$0.02 per share Price / Cash Flow3.99 Book Value$0.16 per share Price / Book0.54Miscellaneous Outstanding Shares390,430,000Free Float316,291,000Market Cap$33.58 million OptionableNot Optionable Beta2.90 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (OTCMKTS:MRMD) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MariMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MariMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.